Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

2110 - A Phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas


30 Sep 2019


Poster Display session 3



Tumour Site



Lin Shen


Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253


L. Shen1, J. Li2, N. Xu3, B. Xing4, Q. Zhang5, Y. Zhao6, J. Cao7, J. Ding8, J. Wang9, Y. Wang9, H. Dai9

Author affiliations

  • 1 Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, 100142 - Beijing/CN
  • 2 Oncology, Shanghai East Hospital, Tongji University School of Medicine, 200000 - shanghai/CN
  • 3 Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, 310003 - Hangzhou/CN
  • 4 Hepatobiliary And Pancreatic Surgery, Beijing Cancer Hospital, 100142 - Beijing/CN
  • 5 Medical Oncology, Harbin Medical University Cancer Hospital, Harbin/CN
  • 6 Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou/CN
  • 7 Medical Oncology, Fudan University Shanghai Cancer Center, 200000 - Shanghai/CN
  • 8 Clinical And Ra, CStone Pharmaceuticals (Su Zhou) Co., Ltd., Suzhou/CN
  • 9 Clinical And Ra, CStone Pharmaceuticals (Su Zhou) Co., Ltd., 201203 - Suzhou/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2110


CS1001 is a first full-length, fully human anti-PD-L1 mAb developed by the OMT transgenic rat platform, which mirrors natural IgG4 human antibody with expected pharmacokinetics (PK) profiles, and may potentially reduce the risk of immunogenicity and toxicity in pts. This first-in-human Phase Ia/Ib study of CS1001 was conducted to evaluate the safety, tolerability, PK profile, and anti-tumor activity of CS1001 in pts with advanced solid tumors or lymphomas.


Pts with advanced solid tumors or lymphomas were enrolled in the dose escalation Phase Ia, receiving CS1001, Q3W, IV, at escalating doses from 3, to 10, 20, 40 mg/kg and 1200 mg fixed dose. Dose escalation followed a 3 + 3 dose escalation scheme. Dose-limiting toxicity (DLT) was evaluated within 3 weeks after the initial dose. Pts with various tumor types were enrolled in the dose expansion Phase Ib to assess anti-tumor activity and safety, including GC, cholangiocarcinoma, NSCLC, HCC, etc. Safety was assessed by monitoring the frequency and severity of adverse events (AEs) per NCI CTCAE v4.03, tumor response was assessed per RECIST v1.1 (solid tumors) or Lugano 2014 (lymphomas).


As of 30 Nov 2018, 29 pts, median age of 53 (23-75) years, were enrolled in Phase Ia, 3 mg/kg (N = 3); 10 mg/kg (4); 20 mg/kg (3); 40 mg/kg (3) and 1200 mg fixed dose (16). 20 pts discontinued treatment, mostly due to disease progression (14). 2 pts discontinued treatment due to AEs (Grade [G] 4 hepatic function abnormal and G3 pulmonary tuberculosis, neither of which were related to CS1001). Median treatment duration was 126 (21-408+) days. No DLTs were observed. The most frequent TRAEs included anaemia (48.3%) and proteinuria (44.8%). SAEs were reported in 6 pts and they were not related to CS1001. irAEs occurred in 7 pts. Among the 29 pts, 7 (24%) pts had PR, mDoR was not reached. In Phase Ib, 162 pts were enrolled as of 15 Mar 2019.


CS1001 is well tolerated without DLT across the dose levels investigated. Evidence of anti-tumor activities was observed. Currently, 1200 mg fixed dose Q3W is being explored in various tumor types in Phase Ib, safety and efficacy results of selected Phase Ib expansion arms will be reported at the conference presentation.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

CStone Pharmaceuticals (Su Zhou) Co., Ltd.


CStone Pharmaceuticals (Su Zhou) Co., Ltd.


J. Ding: Full / Part-time employment: CStone Pharmaceuticals. J. Wang: Full / Part-time employment: CStone Pharmaceuticals. Y. Wang: Full / Part-time employment: CStone Pharmaceuticals. H. Dai: Full / Part-time employment: CStone Pharmaceuticals. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.